Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2020 | Duvelisib for COVID-19

John DiPersio • 1 Sep 2020
SOHO 2020
General CAR-T Dasatinib Duvelisib

John DiPersio, MD, PhD, Washington University, St. Louis, MO, outlines a study evaluating the use of duvelisib, a PI3K inhibitor, for COVID-19, an agent initially investigated due to its identification as a mediator of immune response in models for cytokine release syndrome (NCT04372602). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from John DiPersio

4:02
Identifying the optimal toxic payloads for antibody-based SCT conditioning using SAv-drug conjugates
John DiPersio • 21 Feb 2023
5:08
LBA: CD33 CRISPR/Cas9 gene-edited donor allograft in patients with AML at risk of relapse post-HSCT
John DiPersio • 21 Feb 2023
4:13
ALL highlights: tisa-cel reinfusion in B-ALL & targeting CD5 and CD7 with CAR-Ts in T-ALL
John DiPersio • 21 Feb 2023
4:19
Advantages & concerns associated with the use of ADC-based conditioning in SCT recipients
John DiPersio • 21 Feb 2023

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals